ARVINAS, INC. ARVN
- luxdegalutamide — Metastatic Castration-Resistant Prostate Cancer Phase 2
- luxdegalutamide — Prostate Cancer Phase 1
AR (2 companies · 3 programs)
Companies with an active program directed at AR.
Eikon Therapeutics, Inc. EIKN
- EIK1006 Preclinical